• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Anti-Aging
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

Combination kills cancer

Article

New York - Results from the largest-ever phase III trial in advanced metastatic melanoma, while preliminary, suggest dacarbazine (DTIC) plus an investigational antisense compound (oblimersen sodium, or Genasense) may significantly improve overall survival versus DTIC alone, according to Anna C. Pavlick, D.O.

Related Videos
Related Content
Brittany Scurto, PA-C: How to Discuss an Integrative Medicine Approach With Patients

Brittany Scurto, PA-C: How to Discuss an Integrative Medicine Approach With Patients

Article
The Cutaneous Connection: Make Data-Driven Decisions For Personalized AD Treatment

The Cutaneous Connection: Make Data-Driven Decisions For Personalized AD Treatment

Podcast
Atopic Dermatitis Identified as Possible Risk Factor for Headache Disorders, Migraine

Atopic Dermatitis Identified as Possible Risk Factor for Headache Disorders, Migraine

Article
ReV Up Your Vitiligo Treatment Strategies

ReV Up Your Vitiligo Treatment Strategies

Podcast
Guselkumab Demonstrates Significant Improvement in Psoriasis Symptoms and HRQoL, Reduces Sexual Impairment and Stigmatization

Guselkumab Demonstrates Significant Improvement in Psoriasis Symptoms and HRQoL, Reduces Sexual Impairment and Stigmatization

Article
Nivolumab Plus Talazoparib Does Not Induce Responses in Heavily Pretreated Melanoma

Nivolumab Plus Talazoparib Does Not Induce Responses in Heavily Pretreated Melanoma

Article
© 2024 MJH Life Sciences

All rights reserved.